Skip to main content

Table 1 Patient identification and previous cancer therapies

From: Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes

Patient

Age -yr

Primary Tumor site

Treatment date (months after first diagnosis)

Liver Volume -ccm

CTV -ccm

With ≥10 Gy irradiated Liver Volume -ccm

Chemotherapy prior to brachytherapy

Chemotherapy during follow-up

Liver resection or local treatment prior to brachytherapy

1

84

Colon

79

1063

66.7

249.5

n/a

none

Right hemihepatectomy, RFA

2

69

Gastric

16

1720

340.4

689

CAP+DOC, CAP

none

none

3

66

Lung

10

2135

30.6

205

none

GEM

RFA

4

66

Colon

13

1296

3.64

19

FOLFOX

none

none

5

66

Breast

83

1206

2.7

79.5

TAM, END+EPI+5FU/FA, EXE

EXE

none

6

63

Breast

18

1301

41.5

277.7

VP 16+JM8, DOC

GEM, DOC+CAP

none

7

72

Colon

30

1499

23.1

141

5FU/FA, FOLFOX

none

Wedge resection S4

8

30

Breast

12

1334

9.2

90.6

DOC+EPI, TAM+LEU, VIN+ Anti-Her-2/neu, 5FU/FA

CAP

none

9

61

Breast

n/a

1406

15.1

91.3

none

none

Wedge resection S4

10

70

Colon

14

2672

20.5

181

5FU/FA

none

none

11

58

Colon

49

1531

36.4

236

5FU/FA, FOLFIRI, FOLFOX

none

none

12

69

Colon

43

1610

100.7

381.6

FOLFIRI, FOLFOX, 5FU/FA, Anti-EGFR +CPT11

Anti-EGFR+CPT11

none

13

61

Colon

n/a

1350

123.6

327.6

FOLFOX+Anti-VEGF, 5FU/FA,

FOLFOX

Right hemihepatectomy, RFA

14

72

Renal

n/a

1170

1.7

49.4

none

none

Wedge resection, RFA

15

55

Colon

56

1484

58.5

370

FOLFIRI, FOLFOX

none

Right hemihepatectomy

16

62

Colon

20

1247

4.9

104.5

FOLFOX

none

none

17

56

Renal

6

822

30.5

137.7

none

SOR

none

18

55

Colon

22

1170

7.3

145

CAP+L-OHP, CAP+L-OHP+ Anti-VEGF

none

Right hemihepatectomy

19

69

Breast

34

1073

10.1

60.1

EPI+DOC, Anti-Her-2/neu +CAP+VIN, SDX 105, DOC

none

none

20

53

Breast

125

1054

0.8

22.2

VP 16+CAR, DOC+ADR, TAM, EXE, LET, 5FU/FA+CTX+EPI, FUL, GEM

none

none

21

52

Breast

16

1650

7.1

102

VP 16+JM8, LET

CAP

none

22

76

Renal

156

930

2.9

14.7

none

none

Wedge resection, RFA

23

77

Breast

80

1503

28.9

100.7

CAP

none

none

  1. Abbreviations: Bendamustine (SDX 105), Bevacizumab (Anti-VEGF), Capecitabine (CAP), Carboplatin (JM8), Cetuximab (Anti-EGFR), Cyclophosphamide (CTX), Docetaxel (DOC), Doxorubicin (ADR), Endoxane (END), Epirubicin (EPI), Etoposide (VP 16), Exemestan (EXE), 5-Fluorouracil (5FU), Folic acid (FA), 5-Fluorouracil/Folic acid +Irinotecan (FOLFIRI), 5-Fluorouracil/Folic acid +Oxaliplatin (FOLFOX), Fulvestrant (FUL), Gemcitabine (GEM), Irinotecan (CPT 11), Letrozole (LET), Leuprorelin (LEU), Oxaliplatin (L-OHP), Sorafenib (SOR), Tamoxifen (TAM), Trastuzumab (Anti-Her-2/neu), Vinorelbine (VIN).
  2. Combined applications are marked by +. Comma marks indicate sequential chemotherapeutic regimens.
  3. Clinical Target Volume (CTV), Radiofrequency Ablation (RFA)